Bloomberg News

Abbott Laboratories (ABT - Get Report) posted third quarter earnings that were largely in-line with Wall Street forecasts Wednesday, but narrowed its full-year profit forecast.

Abbott said earnings for the three months ending in September came in at 84 cents per share, up 3.7% from the same period last year and matching the Street consensus forecast. Group revenues also fell in-line with analysts's estimates, as world wide sales rose 5.8% to $8.1 billion.

Looking into the final months of 2019, Abbott said it sees full-year earnings from continuing operations of between $3.23 and $3.25 per share, down 2 cents from the higher end of the forecast it published in mid-July. 

"We're performing exceptionally well across several areas," said CEO Miles White. "We're right on track to achieve ongoing EPS and organic sales growth at the upper-end of our initial guidance ranges for the year."

Abbott shares were marked 2.12% lower at the start of trading following the earnings release to change hands at $80.33 each, a move that would trim the stock's year-to-date gain to around 11.3%.